| Tofacitinib or adalimumab versus placebo in rheumatoid arthritis RF Van Vollenhoven, R Fleischmann, S Cohen, EB Lee, ... New England Journal of Medicine 367 (6), 508-519, 2012 | 1095 | 2012 |
| Tofacitinib versus methotrexate in rheumatoid arthritis EB Lee, R Fleischmann, S Hall, B Wilkinson, JD Bradley, D Gruben, ... New England Journal of Medicine 370 (25), 2377-2386, 2014 | 842 | 2014 |
| Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci N Mizuki, A Meguro, M Ota, S Ohno, T Shiota, T Kawagoe, N Ito, J Kera, ... Nature genetics 42 (8), 703-706, 2010 | 606 | 2010 |
| Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an … R Fleischmann, M Cutolo, MC Genovese, EB Lee, KS Kanik, S Sadis, ... Arthritis & Rheumatism 64 (3), 617-629, 2012 | 455 | 2012 |
| Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials SB Cohen, Y Tanaka, X Mariette, JR Curtis, EB Lee, P Nash, KL Winthrop, ... Annals of the rheumatic diseases 76 (7), 1253-1262, 2017 | 406 | 2017 |
| Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological … D van der Heijde, JCC Wei, M Dougados, P Mease, A Deodhar, ... The Lancet 392 (10163), 2441-2451, 2018 | 371 | 2018 |
| Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind … GR Burmester, Y Lin, R Patel, J Van Adelsberg, EK Mangan, ... Annals of the rheumatic diseases 76 (5), 840-847, 2017 | 359 | 2017 |
| Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies J Wollenhaupt, J Silverfield, EB Lee, JR Curtis, SP Wood, K Soma, ... The Journal of rheumatology 41 (5), 837-852, 2014 | 355 | 2014 |
| Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study J Wollenhaupt, EB Lee, JR Curtis, J Silverfield, K Terry, K Soma, C Mojcik, ... Arthritis research & therapy 21, 1-18, 2019 | 302 | 2019 |
| Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis EH Kang, EB Lee, KC Shin, CH Im, DH Chung, SK Han, YW Song Rheumatology 44 (10), 1282-1286, 2005 | 284 | 2005 |
| Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial JK Park, YJ Lee, K Shin, YJ Ha, EY Lee, YW Song, Y Choi, KL Winthrop, ... Annals of the rheumatic diseases 77 (6), 898-904, 2018 | 240 | 2018 |
| Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen‐week results from a phase III randomized, double‐blind, placebo‐controlled … A Deodhar, D Poddubnyy, C Pacheco‐Tena, C Salvarani, ... Arthritis & rheumatology 71 (4), 599-611, 2019 | 238 | 2019 |
| The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis KL Winthrop, J Silverfield, A Racewicz, J Neal, EB Lee, P Hrycaj, ... Annals of the rheumatic diseases 75 (4), 687-695, 2016 | 231 | 2016 |
| Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial A Deodhar, D van der Heijde, LS Gensler, TH Kim, WP Maksymowych, ... The Lancet 395 (10217), 53-64, 2020 | 222 | 2020 |
| Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement P Nash, A Kerschbaumer, T Dörner, M Dougados, RM Fleischmann, ... Annals of the rheumatic diseases 80 (1), 71-87, 2021 | 210 | 2021 |
| Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids JW Park, JR Curtis, J Moon, YW Song, S Kim, EB Lee Annals of the rheumatic diseases 77 (5), 644-649, 2018 | 210 | 2018 |
| Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme JR Curtis, EB Lee, IV Kaplan, K Kwok, J Geier, B Benda, K Soma, L Wang, ... Annals of the Rheumatic Diseases 75 (5), 831-841, 2016 | 191 | 2016 |
| Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. HA Kim, CD Yoo, HJ Baek, EB Lee, C Ahn, JS Han, S Kim, JS Lee, ... Clinical and experimental rheumatology 16 (1), 9-13, 1998 | 188 | 1998 |
| Adiponectin is a potential catabolic mediator in osteoarthritis cartilage EH Kang, YJ Lee, TK Kim, CB Chang, JH Chung, K Shin, EY Lee, EB Lee, ... Arthritis research & therapy 12, 1-11, 2010 | 180 | 2010 |
| Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme SB Cohen, Y Tanaka, X Mariette, JR Curtis, EB Lee, P Nash, KL Winthrop, ... RMD open 6 (3), e001395, 2020 | 150 | 2020 |
